<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>Email Template - Geometric</title><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:12.0pt;
font-family:"Times New Roman","serif";
color:windowtext;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:45.0pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:normal;}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:27.0pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:18.0pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:bold;}
h4
{mso-style-priority:9;
mso-style-link:"Heading 4 Char";
margin-top:9.0pt;
margin-right:0cm;
margin-bottom:9.0pt;
margin-left:0cm;
line-height:normal;
font-size:13.5pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#4B98D7;
text-decoration:none none;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#4B98D7;
text-decoration:none none;}
p
{mso-style-priority:99;
margin:0cm;
margin-bottom:.0001pt;
line-height:18.0pt;
font-size:13.0pt;
font-family:"Georgia","serif";
color:#333333;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
span.Heading4Char
{mso-style-name:"Heading 4 Char";
mso-style-priority:9;
mso-style-link:"Heading 4";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;
font-style:italic;}
span.EmailStyle23
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor=white lang=EN-CA link="#4B98D7" vlink="#4B98D7"><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below wrt a survey.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Jackie Manthorne [mailto:jmanthorne=survivornet.ca@cmail1.com] <b>On Behalf Of </b>Jackie Manthorne<br><b>Sent:</b> April 13, 2014 8:06 AM<br><b>To:</b> Glen Tolhurst<br><b>Subject:</b> Participate in CCSN's Survey about Xofigo (radium-223 dichloride), which targets bone metastases in men with castration-resistant prostate cancer<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:white'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal><img width=624 height=12 id="_x0000_i1025" src="http://i5.cmail1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/spacer-top.jpg"><o:p></o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td width=221 style='width:165.75pt;padding:0cm 0cm 0cm 0cm'><p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Is this email not displaying correctly?<o:p></o:p></span></p></td><td width=285 valign=top style='width:213.75pt;padding:0cm 0cm 0cm 0cm'><p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><a href="http://ccsn.cmail1.com/t/r-e-xqlhid-tiliitlrdd-r/" id=vw><b><span style='color:#333333;background:#E9E8E8'>View it in a web browser</span></b></a> <o:p></o:p></span></p></td><td width=118 valign=top style='width:88.5pt;padding:0cm 0cm 0cm 0cm'><p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><a href="http://ccsn.forwardtomyfriend.com/r-tiliitlrdd-F12A0EB2-xqlhid-l-y" id=ff><b><span style='color:white;background:#989480'>Forward to a friend</span></b></a> <o:p></o:p></span></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td width=624 valign=top style='width:468.0pt;padding:0cm 0cm 0cm 0cm'><p><img border=0 width=624 height=10 id="_x0000_i1026" src="http://i7.cmail1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt' id=email-content><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='height:15.0pt'><td valign=top style='padding:0cm 0cm 0cm 0cm;height:15.0pt'><p class=MsoNormal><img border=0 width=622 height=313 id="_x0000_i1027" src="http://i6.cmail1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/img1.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr style='height:22.5pt'><td width=624 style='width:468.0pt;padding:0cm 0cm 0cm 0cm;height:22.5pt'><p class=MsoNormal><img border=0 width=624 height=13 id="_x0000_i1028" src="http://i8.cmail1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break-2.jpg"><o:p></o:p></p></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td width=624 valign=top style='width:468.0pt;padding:0cm 0cm 0cm 0cm'><h3>Participate in CCSN's Survey about Xofigo (radium-223 dichloride), which targets bone metastases in men with castration-resistant prostate cancer<o:p></o:p></h3><p> <o:p></o:p></p><p>The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing advanced stages of prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication called Xofigo (radium-223 dichloride) that targets bone metastases in men with castration-resistant prostate cancer. This new medication will soon be going through the Ontario Drug Benefit Programs drug review process that invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.<o:p></o:p></p><p> <o:p></o:p></p><p>The survey will be available starting now and remain open until April 15.<o:p></o:p></p><p> <o:p></o:p></p><p>Click <a href="http://ccsn.cmail1.com/t/r-l-xqlhid-tiliitlrdd-h/">here</a> to access the survey.<o:p></o:p></p><p> <o:p></o:p></p><p>Thank you for your participation.<o:p></o:p></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr style='height:30.0pt'><td style='padding:0cm 0cm 0cm 0cm;height:30.0pt'><p class=MsoNormal><img border=0 width=624 height=10 id="_x0000_i1029" src="http://i7.cmail1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr style='height:22.5pt'><td width=624 style='width:468.0pt;padding:0cm 0cm 0cm 0cm;height:22.5pt'><p class=MsoNormal><img border=0 width=624 height=13 id="_x0000_i1030" src="http://i8.cmail1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break-2.jpg"><o:p></o:p></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><p>Canadian Cancer Survivor Network<br>1750 Courtwood Crescent, Suite 210<br>Ottawa, ON K2C 2B5<br>Telephone: 613-898-1871<br>Email: <a href="mailto:info@survivornet.ca">info@survivornet.ca</a><br>Website: <a href="http://www.survivornet.ca">www.survivornet.ca</a><o:p></o:p></p><p> <o:p></o:p></p><p><strong><span style='font-family:"Georgia","serif"'>Twitter pages</span></strong><br>@survivornet.ca<br>@bestbreastnews, which concentrates on information on breast health and breast cancer<br>@prostatepost, which concentrates on information on prostate cancer<br>@canadianmeso, which is about asbestos and mestothelioma<br>@CanadaCINV, which is about chemo-induced nausea and vomiting<o:p></o:p></p><p> <o:p></o:p></p><p><strong><span style='font-family:"Georgia","serif"'>Facebook</span></strong><br><a href="http://www.facebook.com/CanadianSurvivorNet">http://www.facebook.com/CanadianSurvivorNet</a><br>Our second FB page is about asbestos and mesothelioma: <a href="https://www.facebook.com/CanadianMeso">https://www.facebook.com/CanadianMeso</a><o:p></o:p></p><p> <o:p></o:p></p><p><strong><span style='font-family:"Georgia","serif"'>Pinterest</span></strong><br><a href="http://pinterest.com/survivornetwork/">http://pinterest.com/survivornetwork/</a><o:p></o:p></p><p> <o:p></o:p></p><p><strong><span style='font-family:"Georgia","serif"'>Blog</span></strong><br>Jackie Manthorne's Cancer Blog: <a href="http://jackiemanthornescancerblog.blogspot.com/">http://jackiemanthornescancerblog.blogspot.com/</a><o:p></o:p></p><p><br><br><strong><span style='font-family:"Georgia","serif"'>Weekly newsletter</span></strong><br>Subscribe to our weekly newsletter <a href="http://paper.li/survivornetca/1373569518">http://paper.li/survivornetca/1373569518</a><o:p></o:p></p><p> <o:p></o:p></p><p>This eletter is published once a month. Occasional alerts may also be sent.<o:p></o:p></p><p>You are receiving this newsletter because you subscribed to it. If you are no longer interested in receiving it, please click below to unsubscribe.<br><br>If you received this eletter from a friend or colleague, you can subscribe by sending a message to <a href="mailto:info@survivornet.ca">info@survivornet.ca</a> or by going to the front page of our website at <a href="http://www.survivornet.ca">www.survivornet.ca</a> and signing up. News and involvement opportunities are always being added.<o:p></o:p></p><p> <o:p></o:p></p><p><a href="http://ccsn.cmail1.com/t/r-u-xqlhid-tiliitlrdd-j/">Unsubscribe instantly.</a><o:p></o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='height:22.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:22.5pt'></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table><p class=MsoNormal><img border=0 width=1 height=1 id="_x0000_i1031" src="https://cmail1.com/t/r-o-xqlhid-tiliitlrdd/o.gif"><o:p></o:p></p></div></body></html>